Doxil Ovarian Cancer Symptom Study Could Confirm Accelerated Approval
Executive Summary
A clinical trial showing improvement of symptoms in refractory ovarian cancer patients would support full approval of Alza's Doxil for that indication, FDA's Oncologic Drugs Advisory Committee said June 8.